Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00005025
Recruitment Status : Unknown
Verified March 2003 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : May 5, 2003
Last Update Posted : November 6, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells.

PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating women who have refractory or relapsed ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.

Condition or disease Intervention/treatment Phase
Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Cavity Cancer Biological: herpes simplex thymidine kinase Drug: ganciclovir Phase 2

Detailed Description:


  • Determine the efficacy and safety of in vivo gene therapy with herpes simplex thymidine kinase (HSVtk) vector producer cells (VPC) followed by ganciclovir in women with refractory or relapsed ovarian epithelial adenocarcinoma, fallopian tube cancer, or peritoneal cancer.
  • Determine any development of systemic immunity to this regimen or tumor in these patients.
  • Determine the toxic effects of intraperitoneal HSVtk VPC in these patients.

OUTLINE: All patients receive an intraperitoneal catheter prior to infusion.

Patients receive herpes simplex thymidine kinase (HSVtk) vector producer cells (VPC) IP over 15-60 minutes on day 0, followed by ganciclovir IV 2 times daily on days 28-41. Treatment repeats for up to 3 courses in patients with stable or responsive disease.

Patients are followed every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 14-20 patients will be accrued for this study within 18-24 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: A Phase II Trial of In Vivo Gene Therapy With the Herpes Simplex Thymidine Kinase for the Treatment of Ovarian Cancer
Study Start Date : June 2000

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed, refractory or relapsed, ovarian epithelial adenocarcinoma, fallopian tube cancer, or extraovarian peritoneal cancer for which no curative therapy exists

    • Must have tissue available from tumor biopsy to grow tumor cells ex vivo
    • Must have failed standard therapy with both a platinum agent (cisplatin or carboplatin) and paclitaxel
  • Site of disease must be less than 5 cm in greatest diameter
  • Evaluable disease by CT scan, physical exam, or laparoscopy
  • No significant peritoneal fibrosis either from disease or prior surgery

    • Surgical lysis of adhesions allowed



  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • WBC greater than 2,000/mm3
  • Absolute neutrophil count at least 1,000/mm3
  • Platelet count at least 50,000/mm3
  • Hemoglobin at least 8.5 g/dL (without transfusion)


  • Bilirubin no greater than 2.0 mg/dL
  • SGOT or SGPT no greater than 4 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 4 times ULN
  • Hepatitis B surface antigen test required prior to study if transaminases greater than 2.0 times ULN
  • No hepatitis B surface antigen
  • Amylase normal
  • PT and PTT normal


  • Creatinine no greater than 2.0 mg/dL OR
  • Creatinine clearance at least 50 mL/min


  • No cardiac dysfunction by history and exam
  • No ischemic heart disease that may be considered anesthetic or operative risk


  • No lung disease that may be considered anesthetic or operative risk


  • HIV negative
  • Not pregnant or nursing
  • No acute viral, bacterial, or fungal infection requiring medication within 14 days prior to study
  • No patient with greater than 2 L of ascites at the time of intraperitoneal infusion
  • No underlying condition that would preclude compliance
  • No allergies to study reagent


Biologic therapy:

  • Not specified


  • See Disease Characteristics
  • No concurrent chemotherapy

Endocrine therapy:

  • Not specified


  • Not specified


  • See Disease Characteristics


  • No concurrent high dose vitamin regimens

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00005025

Layout table for location information
United States, Iowa
Human Gene Therapy Research Institute
Des Moines, Iowa, United States, 50309
Sponsors and Collaborators
John Stoddard Cancer Center at Iowa Methodist Medical Center
Layout table for investigator information
Study Chair: Charles Joseph Link, MD John Stoddard Cancer Center at Iowa Methodist Medical Center
Layout table for additonal information Identifier: NCT00005025    
Other Study ID Numbers: CDR0000067546
First Posted: May 5, 2003    Key Record Dates
Last Update Posted: November 6, 2013
Last Verified: March 2003
Keywords provided by National Cancer Institute (NCI):
recurrent ovarian epithelial cancer
fallopian tube cancer
primary peritoneal cavity cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Fallopian Tube Diseases
Ganciclovir triphosphate
Antiviral Agents
Anti-Infective Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action